<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754854</url>
  </required_header>
  <id_info>
    <org_study_id>EA115620</org_study_id>
    <nct_id>NCT04754854</nct_id>
  </id_info>
  <brief_title>Reduction of Blood Recirculation in Veno-Venous ECMO</brief_title>
  <official_title>Reduction of Blood Recirculation in Veno-Venous ECMO Through Ultrasound Dilution Measurements (ECMO Circulation Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood which recirculates through the circuit of a veno-venous Extracorporeal Membrane&#xD;
      Oxygenation (V-V ECMO) does not contribute to the systemic oxygenation of a patient on V-V&#xD;
      ECMO and is called the recirculation fraction (Rf). Theoretically, the optimization of ECMO&#xD;
      blood flow is possible using Rf measurements.&#xD;
&#xD;
      A prospective, observational study will be performed measuring the Rf of total ECMO blood&#xD;
      flow in patients with acute respiratory distress syndrome (ARDS) on V-V ECMO with an&#xD;
      ultrasound dilution technique.&#xD;
&#xD;
      ECMO blood flow will be optimized by reducing ECMO blood flow in accordance with the measured&#xD;
      Rf as long as systemic oxygenation is not compromised.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on data from the 'Blood Recirculation and vvECMO' trial (ClinicalTrials.gov ID:&#xD;
      NCT03200314) (i.e. an expected frequency of successful blood flow reduction of 66.7%), using&#xD;
      a one-sample Chi square test, a two-sided type-1 error of 5%, a power of 80%, a total of 68&#xD;
      patients is needed to show that the proportion of patients with a secure ECMO blood flow&#xD;
      reduction is greater than 50%. Presumably, 136 Patients have to be included into the trial to&#xD;
      study 68 patients with a relevant Rf since not all patients on V-V ECMO suffer from a high&#xD;
      Rf.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Successful ECMO blood flow reduction</measure>
    <time_frame>Once within the first week after initiation of ECMO therapy</time_frame>
    <description>Number of patients with a relevant recirculation fraction and successful ECMO blood flow reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recirculation fraction</measure>
    <time_frame>Once within the first week after initiation of ECMO therapy</time_frame>
    <description>Fraction of blood recirculating through the ECMO circuit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood oxygen content</measure>
    <time_frame>Once within the first week after initiation of ECMO therapy</time_frame>
    <description>Arterial blood oxygen content before vs. after reduction of ECMO blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracorporeal Blood Flow</measure>
    <time_frame>Once within the first week after initiation of ECMO therapy</time_frame>
    <description>ECMO Blood Flow before vs. after reduction of ECMO blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>srporeal Gas flow</measure>
    <time_frame>Once within the first week after initiation of ECMO therapy</time_frame>
    <description>ECMO Sweep Gas flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ECMO therapy</measure>
    <time_frame>Daily until the end of ECMO therapy (approximately 14 days)</time_frame>
    <description>Days on ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannula position and distance</measure>
    <time_frame>Once within the first week after initiation of ECMO therapy</time_frame>
    <description>The distance between the tip of drainage and return cannula will be measured in the existing medical imaging (e.g. CT scans)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right heart dysfunction</measure>
    <time_frame>Once within the first week after initiation of ECMO therapy</time_frame>
    <description>Existing echocardiography will be evaluated for possible right heart dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of mechanical ventilation</measure>
    <time_frame>Entire duration of the ICU stay (approximately 28 days)</time_frame>
    <description>Length of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of ECMO therapy</measure>
    <time_frame>Length of ECMO therapy (approximately 14 days)</time_frame>
    <description>Incidence of cannula or system changes (i.e. due to circuit clotting), complications attributed to ECMO therapy like bleeding complications from the cannulation site, transfusion requirements, hemolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Entire duration of the ICU stay (approximately 28 days)</time_frame>
    <description>ICU mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Entire duration of the ICU stay (approximately 28 days)</time_frame>
    <description>ICU length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ICU-acquired organ dysfunctions and complications</measure>
    <time_frame>Entire duration of the ICU stay (approximately 28 days)</time_frame>
    <description>Cerebral-, cardiovascular-, cardiac- pulmonary-, gastrointestinal- and renal dysfunctions, ICU-acquired infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECMO blood flow over time</measure>
    <time_frame>Daily until the end of ECMO therapy (approximately 14 days)</time_frame>
    <description>ECMO blood and sweep gas flow over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECMO sweep gas flow over time</measure>
    <time_frame>Daily until the end of ECMO therapy (approximately 14 days)</time_frame>
    <description>ECMO sweep gas flow over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility at ICU discharge</measure>
    <time_frame>Discharge from the ICU (approximately 28 days)</time_frame>
    <description>Level of mobility the patient has reached at ICU discharge (recumbent, sitting, standing, walking with help, walking independently)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weaning level at ICU discharge</measure>
    <time_frame>Discharge from the ICU (approximately 28 days)</time_frame>
    <description>Level of weaning reached at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of mechanical ventilation at ICU discharge</measure>
    <time_frame>Discharge from the ICU (approximately 28 days)</time_frame>
    <description>Status of mechanical ventilation at ICU discharge including all relevant settings and parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of organ dysfunction at ICU discharge</measure>
    <time_frame>Discharge from the ICU (approximately 28 days)</time_frame>
    <description>Sepsis-related Organ Failure Assessment Score at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of consciousness at ICU discharge</measure>
    <time_frame>Discharge from the ICU (approximately 28 days)</time_frame>
    <description>Glasgow Coma Scale at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of disease severity</measure>
    <time_frame>Discharge from the ICU (approximately 28 days)</time_frame>
    <description>Acute Physiology And Chronic Health Evaluation at ICU discharge</description>
  </secondary_outcome>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients aged 18 years or older&#xD;
&#xD;
          -  ARDS&#xD;
&#xD;
          -  veno-venous ECMO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
&#xD;
          -  hemodynamic instability during measurement of recirculation&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  inability to obtain patient's consent or consent of legal guardian&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients aged 18 years or older requiring veno-venous ECMO for treatment of refractory&#xD;
        hypoxemia in ARDS.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Russ, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University Hospital Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp A Pickerodt, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University Hospital Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Skrypnikov, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University Hospital Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Weber-Carstens, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University Hospital Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steffen Weber-Carstens, Prof. Dr. med.</last_name>
    <phone>0049-30450651005</phone>
    <email>steffen.weber-carstens@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Russ, Dr. med.</last_name>
    <phone>0049-30450651268</phone>
    <email>martin.russ@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Weber-Carstens, Prof. Dr. med.</last_name>
      <phone>0049-30450651055</phone>
      <email>steffen.webercarstens@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Russ, Dr. med.</last_name>
      <phone>0049-30450651268</phone>
      <email>martin.russ@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Steffen Weber-Carstens</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

